Probiotic Strains for Antibiotic-Associated Diarrhea in Children: Which Species Work

Antibiotic-associated diarrhea (AAD) occurs in roughly 11-40 percent of children receiving outpatient antibiotic courses. Two probiotic species have substantially better evidence for prevention than the generic "multi-strain" formulas dominating retail shelves: Lactobacillus rhamnosus GG and Saccharomyces boulardii. The strain specificity matters more than the marketing implies.

The Cochrane verdict

The 2019 Cochrane review on probiotics for AAD prevention in children pooled 33 RCTs (n=6,352) and concluded with moderate certainty that probiotics reduce the risk of AAD from approximately 19 percent to 8 percent — a number needed to treat of about nine. The most robust evidence supported L. rhamnosus GG and S. boulardii at doses of at least 5 billion CFU/day, started within 48 hours of antibiotic initiation and continued for the duration of treatment [1].

L. rhamnosus GG specifically

A meta-analysis of 12 pediatric trials specifically of L. rhamnosus GG found relative risk reduction of approximately 50 percent versus placebo or no treatment, with the strongest effect in children under five and those on broad-spectrum penicillins or cephalosporins [2]. Most positive trials used at least 10 billion CFU/day, and the protective effect was lost when probiotic was started after antibiotic course was already underway.

S. boulardii specifically

S. boulardii is a yeast, so unlike bacterial probiotics it is not killed by the antibiotic itself. A meta-analysis of nine pediatric RCTs reported a 0.42 relative risk of AAD with S. boulardii compared with placebo [3]. The yeast has also shown benefit for preventing Clostridioides difficile-associated diarrhea, though pediatric data on that specific endpoint are sparser. Caution: S. boulardii should not be used in immunocompromised children or those with central venous catheters due to rare fungemia case reports [4].

What about other strains

Trials of Bifidobacterium-only formulations, generic "multi-strain" products, and synbiotics in pediatric AAD have produced inconsistent results. The American Academy of Pediatrics' 2021 clinical report explicitly noted that the evidence for AAD prevention is strain-specific and warned against extrapolating efficacy across products [5].

Practical guidance

For a child starting an outpatient antibiotic course, the trial-supported approach is to begin L. rhamnosus GG 10 billion CFU/day or S. boulardii 250-500 mg/day within 48 hours, continuing through the antibiotic course and for one week after [6]. Refrigeration requirements for live bacterial products matter; S. boulardii is shelf-stable, which simplifies adherence for travel or shared-care settings. Children with severe immunocompromise, indwelling catheters, or short-gut syndrome should not start probiotics without specialist input [7].

The Clostridioides difficile angle

Pediatric C. difficile infection is less common than in adults but increasing in incidence, particularly in children with inflammatory bowel disease or recent broad-spectrum antibiotic exposure. Trials specifically examining probiotic prevention of pediatric CDAD are limited, but extrapolation from adult data suggests S. boulardii may reduce recurrence in children with established CDAD who are receiving vancomycin or fidaxomicin [8]. This is an off-label use that should be coordinated with the infectious-disease or gastroenterology team.

The cost-benefit and equity question

Probiotic prophylaxis adds a small daily cost for the duration of antibiotic therapy plus a week, which is generally tolerable but not zero. In community settings with high antibiotic prescribing rates, the cumulative cost matters. The simplest rule for families: if a child is starting a course of amoxicillin-clavulanate, clindamycin, or any broad-spectrum agent, an evidence-supported probiotic (LGG or S. boulardii) started day one is a reasonable, low-risk addition. Bargain multi-strain blends without species-level evidence are not equivalent and should not be assumed to provide the same benefit.